175 related articles for article (PubMed ID: 10375295)
21. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroids: no drug prevention of fractures needed.
Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
[TBL] [Abstract][Full Text] [Related]
23. Alendronate for the treatment of osteoporosis in men.
Olszynski WP; Davison KS
Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
[TBL] [Abstract][Full Text] [Related]
24. Prevention of glucocorticoid-induced osteoporosis.
van Brussel MS; Bultink IE; Lems WF
Expert Opin Pharmacother; 2009 Apr; 10(6):997-1005. PubMed ID: 19351276
[TBL] [Abstract][Full Text] [Related]
25. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
[TBL] [Abstract][Full Text] [Related]
26. Gastroenterologists and choosing the right bisphosphonate.
Leder BZ; Kronenberg HM
Gastroenterology; 2000 Sep; 119(3):866-9. PubMed ID: 10982780
[No Abstract] [Full Text] [Related]
27. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
28. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
Soen S
Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
[TBL] [Abstract][Full Text] [Related]
29. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
30. [Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Välimäki MJ
Duodecim; 2001; 117(24):2521-3. PubMed ID: 12183812
[No Abstract] [Full Text] [Related]
31. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Kishimoto M; Oishi A; Motojima S
N Engl J Med; 2006 Nov; 355(20):2156; author reply 2157. PubMed ID: 17108350
[No Abstract] [Full Text] [Related]
32. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
33. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
34. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Takeda S; Kaneoka H; Saito T
Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
[TBL] [Abstract][Full Text] [Related]
35. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
36. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Cruse LM; Valeriano J; Vasey FB; Carter JD
J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
39. [Application of anti-resorptive drugs for the treatment of osteoporosis].
Takada J
Nihon Rinsho; 2006 Feb; 64(2):385-91. PubMed ID: 16454196
[TBL] [Abstract][Full Text] [Related]
40. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Minisola S; Scillitani A; Romagnoli E
N Engl J Med; 2006 Nov; 355(20):2156-7; author reply 2157. PubMed ID: 17120352
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
